BINEX Co., Ltd. (053030.KQ)

KRW 17490.0

(-3.95%)

Market Cap (In KRW)

557.01 Billion

Revenue (In KRW)

154.82 Billion

Net Income (In KRW)

4.67 Billion

Avg. Volume

3.58 Million

Currency
KRW
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
8190.0-27300.0
PE
-
EPS
-
Beta Value
0.693397
ISIN
KR7053030003
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Won-Seok Kim
Employee Count
-
Website
https://www.bi-nex.co.kr
Ipo Date
2001-08-07
Details
BINEX Co., Ltd. operates as a pharmaceutical company in South Korea. It offers bisroot products; GI tract and antispasmodic, and antiulcer agents; NSAIDs; cardiovascular and urology products; hepatic protectors; ointments and creams; ophthalmic solutions; CNS agents; digestive products; constipation and blood circulation products; antibiotic and antifungal agents; cough and cold remedy products; vitamins and nutrients; antihistamine products; antivertigo products; and OTC products. BINEX Co., Ltd. has a co-development partnership with Genexine, Inc. to develop COVID-19 vaccine. The company was founded in 1957 and is based in Incheon, South Korea.